Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Effect of Dapagliflozin on Blood Glucose Level and Renal Safety in Patients With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Female or male aged ≥18 years and \<75 years.~* History of T2DM for more than 12 months.~* Inadequate glycemic control, defined as HbA1c ≥7.0% and ≤11%~* Stable anti-diabetic treatment regimen~* Renal impairment: CKD 3A~Exclusion Criteria:~* Women of childbearing potential who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period.~* History of diabetic ketoacidosis or hyperosmolar nonketotic coma.~* Severe uncontrolled hypertension defined as SBP ≥180 mmHg and/or Diastolic Blood Pressure (DBP) ≥110 mmHg~* Any of the following Cardiovascular (CV)/Vascular Diseases within 3 months of prior to signing the consent at visit 1:~Myocardial infarction, Cardiac surgery or revascularization(CABG/PTCA), Unstable angina, Unstable heart failure (HF), HF New York Heart Association (NYHA) Class IV,Transient ischemic attack (TIA) or significant cerebrovascular disease, Unstable or previously undiagnosed arrhythmia.~* History of any biopsy or imaging verifying intercurrent kidney disease (such as glomerular nephritis or sign of renal artery stenosis) other than diabetic nephropathy or diabetic nephropathy with nephrosclerosis.~* Significant hepatic disease, including, but not limited to, chronic active hepatitis and/or severe hepatic insufficiency.~* Ongoing treatment with any SGLT2-inhibitor, GLP-1 analogue, or rapid/short acting insulins at screening.~* Participation in another clinical study with an Investigational Product (IP) during the last 30 days prior to signing the consent at visit 1.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 74 Years
- Healthy Volunteers: f

Study Arms:
- Dapagliflozin (Type: EXPERIMENTAL): 10 mg Tablets, Oral, Once daily, 24 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Matching placebo to Dapagliflozin 10 mg tablet. Oral, Once daily, 24 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).